The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Robert A. Hauser

University of South Florida

Tampa

FL 33606

USA

[email]@hsc.usf.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University of South Florida, Tampa, FL 33606, USA. 2009
  • Department of Neurology, University of South Florida and Tampa General Healthcare, NPF Center of Excellence, Tampa, USA. 2001 - 2009

References

  1. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. Hauser, R.A., Bronzova, J., Sampaio, C., Lang, A.E., Rascol, O., Theeuwes, A., van de Witte, S.V. Eur. Neurol. (2009) [Pubmed]
  2. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Hauser, R.A., Salin, L., Juhel, N., Konyago, V.L. Mov. Disord. (2007) [Pubmed]
  3. Advances in the pharmacologic management of early Parkinson disease. Hauser, R.A., Zesiewicz, T.A. Neurologist (2007) [Pubmed]
  4. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Hauser, R.A., Rascol, O., Korczyn, A.D., Jon Stoessl, A., Watts, R.L., Poewe, W., De Deyn, P.P., Lang, A.E. Mov. Disord. (2007) [Pubmed]
  5. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Hauser, R.A., Zesiewicz, T.A. Neurology (2006) [Pubmed]
  6. Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. Hauser, R.A., Russ, H., Haeger, D.A., Bruguiere-Fontenille, M., Müller, T., Wenning, G.K. Clin. Neuropharmacol (2006) [Pubmed]
  7. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Hauser, R.A., McDermott, M.P., Messing, S. Arch. Neurol. (2006) [Pubmed]
  8. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Hauser, R.A., Schwarzschild, M.A. Drugs. Aging (2005) [Pubmed]
  9. Parkinson's disease home diary: further validation and implications for clinical trials. Hauser, R.A., Deckers, F., Lehert, P. Mov. Disord. (2004) [Pubmed]
  10. Future therapies for Parkinson's disease. Hauser, R.A., Lyons, K.E. Neurol. Clin (2004) [Pubmed]
  11. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Hauser, R.A., Hubble, J.P., Truong, D.D. Neurology (2003) [Pubmed]
  12. Bilateral human fetal striatal transplantation in Huntington's disease. Hauser, R.A., Furtado, S., Cimino, C.R., Delgado, H., Eichler, S., Schwartz, S., Scott, D., Nauert, G.M., Soety, E., Sossi, V., Holt, D.A., Sanberg, P.R., Stoessl, A.J., Freeman, T.B. Neurology (2002) [Pubmed]
  13. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Hauser, R.A., Holford, N.H. Mov. Disord. (2002) [Pubmed]
  14. Diffuse Lewy Body Disease. Zesiewicz, T.A., Baker, M.J., Dunne, P.B., Hauser, R.A. Curr. Treat. Options. Neurol (2001) [Pubmed]
 
WikiGenes - Universities